PharmaKing

CompanySouth Korea

PharmaKing develops one asset, in phase 2, no development reported (oltipraz in cirrhosis). Mostly small molecule; based in South Korea.

1
Asset
Furthest stage
Phase 2, no development reported
4
Trials
2
Signals

Pipeline

1
  • oltipraz

    Inhibits LXRα-mediated lipogenesis and activates NRF2 antioxidant responses.

    Phase 2, no development reported, Small molecule, cirrhosis, liver fibrosis

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Trials4
  • Signals4
  • Similar companies6

Intelligence